Immunic | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Nash Duane
Immunic | 4: Statement of changes in beneficial ownership of securities-Officer Vitt Daniel
Immunic | 4: Statement of changes in beneficial ownership of securities-Officer Tardio Jason
Immunic | 4: Statement of changes in beneficial ownership of securities-Officer Muehler Andreas
Immunic | 4: Statement of changes in beneficial ownership of securities-Officer Nash Duane
Immunic | 4: Statement of changes in beneficial ownership of securities-Officer Whaley Glenn
Immunic | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Avidity Partners Management LP(9.9%),Avidity Partners Management (GP) LLC(9.9%), etc.
Immunic | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Janus Henderson Group plc(5.7%),Janus Henderson Biotech Innovation Master Fund Ltd(5.2%)
Immunic | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RTW Investments, LP(6.1%),Roderick Wong, M.D.(6.1%)
Immunic | 4: Statement of changes in beneficial ownership of securities-Director Rudick Richard Alan
Immunic | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.21%)
Immunic | SC 13G: Statement of acquisition of beneficial ownership by individuals-Adage Capital Management, L.P.(6.21%),Robert Atchinson(6.21%), etc.
Immunic | 10-Q: Q3 2024 Earnings Report
Immunic | 8-K: Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Immunic | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.21%)
Immunic | 8-K: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
Immunic | 8-K: Immunic hosts multiple sclerosis research and development day
Immunic | 8-K: Addendum No. Six to Employment Agreement
Immunic | 10-Q: Q2 2024 Earnings Report
Immunic | 8-K: Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update